BMC Women's Health (Jun 2008)

The METEX study: Methotrexate versus expectant management in women with ectopic pregnancy: A randomised controlled trial

  • Visser Harry,
  • Verhoeve Harold R,
  • van Santbrink Evert JP,
  • Lips Jos P,
  • Leeuw-Harmsen Loes,
  • Friederich Jaap,
  • Emanuel Mark,
  • Doornbos Johannes PR,
  • Dijkman Antonius B,
  • Boss Erik A,
  • Adriaanse Albert H,
  • Mol Femke,
  • van Mello Norah M,
  • Ankum Willem M,
  • Veen Fulco,
  • Mol Ben W,
  • Hajenius Petra J

DOI
https://doi.org/10.1186/1472-6874-8-10
Journal volume & issue
Vol. 8, no. 1
p. 10

Abstract

Read online

Abstract Background Patients with ectopic pregnancy (EP) and low serum hCG concentrations and women with a pregnancy of unknown location (PUL) and plateauing serum hCG levels are commonly treated with systemic methotrexate (MTX). However, there is no evidence that treatment in these particular subgroups of women is necessary as many of these early EPs may resolve spontaneously. The aim of this study is whether expectant management in women with EP or PUL and with low but plateauing serum hCG concentrations is an alternative to MTX treatment in terms of treatment success, future pregnancy, health related quality of life and costs. Methods/Design A multicentre randomised controlled trial in The Netherlands. Hemodynamically stable patients with an EP visible on transvaginal ultrasound and a plateauing serum hCG concentration Discussion This trial will provide guidance on the present management dilemmas in women with EPs and PULs with low and plateauing serum hCG concentrations. Trial registration Current Controlled Trials ISRCTN 48210491